SecBot SecBot
8-K ·Filed Apr 6, 2026

ONCY

ONCOLYTICS BIOTECH INC
BULLISH
Impact 6/10
Horizonweeks Processed7mo ago SEC0001129928-26-000024
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

Traders should monitor the outcome of the April 16 FDA meeting for guidance on trial design and potential approval pathway, which could serve as a near-term catalyst. Positive alignment with the FDA may support valuation upside in this niche oncology space.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.9500
T+0 close · Apr 6, 2026 · via day close
Latest settled
−5.19%
T+60 · $0.9007
Vs SPY
−18.66%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 6 $0.9500entry
  2. T+1 · 7mo ago −5.26%α −5.33% · $0.9000
  3. T+5 · 7mo ago +10.53%α +6.39% · $1.05
  4. T+20 · 7mo ago −2.11%α −11.09% · $0.9300
  5. T+60 · 5mo ago −5.19%α −18.66% · $0.9007
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Oncolytics Biotech announced a scheduled Type C meeting with the FDA on April 16, 2026, to discuss a registrational pathway for pelareorep in combination with a checkpoint inhibitor for squamous cell anal carcinoma (SCAC). The company plans to propose a single-arm pivotal study enrolling 60–70 patients with objective response rate as the primary endpoint, supported by clinical data showing approximately 30% ORR and 17-month median duration of response.

Key Facts

  • Oncolytics Biotech has scheduled a Type C meeting with the FDA on April 16, 2026, to discuss a registrational pathway for pelareorep in SCAC.
  • The proposed pivotal study is single-arm, enrolling 60–70 patients, with objective response rate (ORR) as the primary endpoint.
  • Clinical data from Cohort 4 of the GOBLET study showed approximately 30% ORR and 17-month median duration of response in late-line SCAC patients.
  • SCAC is a rare cancer with limited second-line treatment options, positioning pelareorep for a potentially efficient approval path.
  • The FDA has previously granted Fast Track designation to pelareorep for colorectal and pancreatic cancers.

Financial Impact

No immediate financial impact disclosed; potential long-term value hinges on FDA agreement and study initiation.

cash flowR&D spendmarket valuation

Risk Factors

  • FDA may not agree to the proposed single-arm pivotal study design or endpoint.
  • Limited patient population and rare cancer indication may constrain commercial revenue potential despite approval.
  • Company remains dependent on future financing or partnerships to fund pivotal development.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001129928-26-000024
Document: oncolyticsfdascacmeetingpr.htm0001129928-26-000024
Document: 0001129928-26-000024-index-headers.html0001129928-26-000024
Document: 0001129928-26-000024-index.html0001129928-26-000024
Document: 0001129928-26-000024.txt0001129928-26-000024

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 6, 2026